Published in Breast Cancer Res Treat on September 04, 2011
Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study. BMJ (2014) 3.43
The benefits and harms of breast cancer screening: an independent review. Br J Cancer (2013) 3.43
Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol (2014) 3.04
Application of a decision analytic framework for adoption of clinical trial results: are the data regarding TARGIT-A IORT ready for prime time? Breast Cancer Res Treat (2014) 2.18
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer (2013) 2.01
Breast cancer screening: the questions answered. Nat Rev Clin Oncol (2012) 1.02
Mammographic screening detects low-risk tumor biology breast cancers. Breast Cancer Res Treat (2014) 1.01
An "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity. Cell Adh Migr (2012) 0.99
Beyond the mammography debate: a moderate perspective. Curr Oncol (2015) 0.97
Disappearing breast cancers. Curr Oncol (2012) 0.91
Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening. J Cancer Res Clin Oncol (2012) 0.86
Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement. Br J Cancer (2013) 0.80
Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study. Diagn Pathol (2014) 0.80
Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses. Cancer Causes Control (2015) 0.78
St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up. Br J Surg (2016) 0.78
Earlier diagnosis of breast cancer outside of a screening programme. Nat Rev Clin Oncol (2013) 0.75
Mammographic screening for breast cancer: Are the chickens coming home to roost? South Asian J Cancer (2013) 0.75
Mammographic screening for breast cancer: A review. J Med Radiat Sci (2013) 0.75
Mathematical models of breast and ovarian cancers. Wiley Interdiscip Rev Syst Biol Med (2016) 0.75
Screening: biology dictates the fate of young women with breast cancer. Nat Rev Clin Oncol (2013) 0.75
The WISDOM Study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer (2017) 0.75
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Overdiagnosis in cancer. J Natl Cancer Inst (2010) 10.31
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Rethinking screening for breast cancer and prostate cancer. JAMA (2009) 7.83
The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med (2008) 7.37
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol (2001) 6.23
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med (2004) 4.84
Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A (2003) 4.47
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol (2007) 3.32
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res (2005) 2.73
Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res (2008) 1.53
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol (2009) 1.44
Flawed inferences about screening mammography's benefit based on observational data. J Clin Oncol (2008) 1.17
Impressive time-related influence of the Dutch screening programme on breast cancer incidence and mortality, 1975-2006. Int J Cancer (2008) 1.07
Solving the overdiagnosis dilemma. J Natl Cancer Inst (2010) 1.03
Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol (2010) 0.86
HRT use in 2001 and 2004 in The Netherlands--a world of difference. Maturitas (2006) 0.86
The screening mammography paradox: better when found, perhaps better not to find. Br J Cancer (2008) 0.83
Breast cancer metastasis: markers and models. Nat Rev Cancer (2005) 9.93
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med (2004) 8.91
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Rethinking screening for breast cancer and prostate cancer. JAMA (2009) 7.83
Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA (2007) 5.74
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol (2007) 5.46
Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med (2009) 5.36
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci U S A (2003) 4.47
Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol (2008) 4.13
Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA (2003) 4.01
Physical activity and breast cancer: a systematic review. Epidemiology (2007) 3.90
Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst (2007) 3.55
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol (2007) 3.32
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30
Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol (2003) 3.24
Anaplastic large-cell lymphoma in women with breast implants. JAMA (2008) 3.23
Incidence of retinoblastoma in children born after in-vitro fertilisation. Lancet (2003) 3.22
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med (2011) 3.16
Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst (2008) 3.13
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst (2005) 3.07
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol (2006) 2.84
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res (2005) 2.73
Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol (2007) 2.68
Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst (2003) 2.65
Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol (2002) 2.63
Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst (2009) 2.55
Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol (2008) 2.49
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (2012) 2.49
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ (2012) 2.44
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst (2002) 2.44
Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol (2009) 2.42
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study. Plast Reconstr Surg (2012) 2.37
Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging (2010) 2.32
Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med (2007) 2.30
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol (2006) 2.28
Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood (2006) 2.18
High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis (2004) 2.13
Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev (2008) 2.12
Hypospadias in sons of women exposed to diethylstilbestrol in utero: a cohort study. Lancet (2002) 2.10
A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res (2008) 2.09
Benefit of semiannual ipsilateral mammographic surveillance following breast conservation therapy. Radiology (2012) 2.07
Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol (2010) 2.04
Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst (2010) 2.04
Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst (2003) 2.02
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat (2008) 1.96
Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy. Ann Surg Oncol (2006) 1.95
Breast tomosynthesis in clinical practice: initial results. Eur Radiol (2009) 1.89
Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med (2010) 1.87
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (2009) 1.84
Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res (2002) 1.84
Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol (2007) 1.83
Expression profiling predicts outcome in breast cancer. Breast Cancer Res (2002) 1.81
Increased risk of ischemic stroke after radiotherapy on the neck in patients younger than 60 years. J Clin Oncol (2002) 1.79
Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer (2011) 1.77
Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol (2008) 1.76
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat (2010) 1.75
Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol (2009) 1.74
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell (2013) 1.73
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. N Engl J Med (2015) 1.70
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.68
Screening program reduced melanoma mortality at the Lawrence Livermore National Laboratory, 1984 to 1996. J Am Acad Dermatol (2008) 1.58
Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer (2007) 1.57
Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood (2009) 1.57
Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol (2006) 1.55
TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet (2010) 1.54
High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol (2012) 1.53
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res (2010) 1.50
Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res (2008) 1.48
[Contribution of lifestyle factors to cancer: secondary analysis of Dutch data over 2010 and a projection for 2020]. Ned Tijdschr Geneeskd (2014) 1.46
The number of retrieved oocytes does not decrease during consecutive gonadotrophin-stimulated IVF cycles. Hum Reprod (2004) 1.46
Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 1.45
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat (2010) 1.42
Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med (2012) 1.42
Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. Int J Radiat Oncol Biol Phys (2006) 1.39
Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat (2011) 1.39
Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics (2007) 1.38
Implications of ALS focality: rostral-caudal distribution of lower motor neuron loss postmortem. Neurology (2007) 1.38
Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys (2009) 1.36
Cardiometabolic differences in children born after in vitro fertilization: follow-up study. J Clin Endocrinol Metab (2008) 1.36
Physical activity and endometrial cancer risk, a systematic review of current evidence. Cancer Epidemiol Biomarkers Prev (2007) 1.35
Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol (2006) 1.34
Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol (2013) 1.34
Socioeconomic status in relation to early menarche among black and white girls. Cancer Causes Control (2008) 1.34
Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res (2004) 1.33
Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res (2009) 1.33
Intra-operative sonography: a valuable aid during breast-conserving surgery for occult breast cancer. Ann Surg Oncol (2007) 1.31
Leukemia and brain tumors among children after radiation exposure from CT scans: design and methodological opportunities of the Dutch Pediatric CT Study. Eur J Epidemiol (2014) 1.30
Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev (2009) 1.29
Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood (2005) 1.28
Causes of physician delay in the diagnosis of breast cancer. Arch Intern Med (2002) 1.27
Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci U S A (2006) 1.27
A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci U S A (2009) 1.27